AG-80308 / AbbVie, Allgenesis Biotherap - LARVOL DELTA

AG-80308, a novel first-in-class ophthalmic solution for the treatment of dry eye disease (ARVO 2024) - "AG-80308 was proven safe when given BID for 3 months. AG-80308 has the potential to be a novel treatment for dry eye disease."

Dry Eye Disease • Ocular Inflammation • Ophthalmology

Allgenesis Announces Encouraging Phase 1b Data Showing AG-80308 Providing Improvements in Multiple Signs and Symptoms in Dry Eye Patients (PRNewswire) - P1b | N=84 | NCT05372107 | Sponsor: Allgenesis Biotherapeutics Inc. | "Allgenesis Biotherapeutics...today announced topline data from the company's Phase 1b clinical trial for AG-80308, a first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop for the treatment of Dry Eye Disease...AG-80308 was considered safe at all doses tested BID for 3 months; improvements in corneal staining, conjunctival staining, and tear production responders; AG-80308 Formulation A 0.001% and Formulation B 0.03% provided the best overall safety, tolerability, and efficacy profile...'We are very encouraged with our data showing that patients are seeing improvements in multiple signs and symptoms from the Phase 1b trial as early as 2 weeks'....Allgenesis has begun preparations to support initiation of the Phase 2 trial in 1Q2024."

New P2 trial • P1 data • Dry Eye Disease • Ophthalmology

A Study of AG-80308 in Dry Eye Patients (clinicaltrials.gov) - P1b | N=84 | Completed | Sponsor: Allgenesis Biotherapeutics Inc. | Recruiting ➔ Completed

Trial completion • Dry Eye Disease • Ophthalmology

A Study of AG-80308 in Dry Eye Patients (clinicaltrials.gov) - P1b | N=80 | Recruiting | Sponsor: Allgenesis Biotherapeutics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Dry Eye Disease • Ophthalmology

A Study of AG-80308 in Dry Eye Patients (clinicaltrials.gov) - P1b | N=80 | Not yet recruiting | Sponsor: Allgenesis Biotherapeutics Inc.

New P1 trial • Dry Eye Disease • Ophthalmology